What if COVID-19 affects the child: which weapons and how to use them

Anedda L.
Writing - Original Draft Preparation
;
Bianchini L.
Member of the Collaboration Group
;
Finco G.
Writing - Review & Editing
;
Fanos V.
Conceptualization
;
2021-01-01

Abstract

– Since the reports in Wuhan (China), in December 2019, of the first cluster of cases of pneumonia caused by the new Coronavirus called 2019-nCoV or SARS-CoV-2, there has been a pandemic spread of the infection. By now, we have no specific therapy to counteract this emergency. The latest epidemiological data suggest that children are just as likely as adults to get infected by the virus. Most of them show mild clinical pictures or are completely asymptomatic, but there is an increased risk for severe disease in infancy (<12 months of age) and in children with underlying medical conditions. In this article, research achievements on the treatment of pediatric SARS-CoV-2 infection are examined.
2021
2019-nCov
COVID-19
Pediatrics
Review
SARS-CoV-2
Treatment
Adenosine Monophosphate
Adolescent
Age Factors
Alanine
Antibodies, Monoclonal, Humanized
Anticoagulants
Antiviral Agents
COVID-19
Carrier State
Child
Child, Preschool
Chloroquine
Continuous Renal Replacement Therapy
Drug Combinations
Extracorporeal Membrane Oxygenation
Glucocorticoids
Humans
Hydroxychloroquine
Immunization, Passive
Immunoglobulins, Intravenous
Immunologic Factors
Infant
Infant, Newborn
Interferon-alpha
Lopinavir
Oseltamivir
Receptors, Cell Surface
Respiration, Artificial
Ribavirin
Ritonavir
SARS-CoV-2
Severity of Illness Index
Thrombosis
Files in This Item:
File Size Format  
3325-3337.pdf

open access

Description: Articolo principale
Type: versione editoriale
Size 866.28 kB
Format Adobe PDF
866.28 kB Adobe PDF View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie